NEW YORK--(BUSINESS WIRE)--Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, announces that the company will be presenting at two conferences this month. James Moe, Ph.D., MBA, President and CEO of Oligomerix, will provide a company overview at the 2020 BIO CEO & Investor Conference and present preclinical data on the company’s small molecule inhibitor of tau self-association at the TAU2020 Global Conference.
Details for both presentations can be found below.
BIO CEO & Investor Conference
Date: Monday, February 10, 2020
Time: 2:30 PM - 2:45 PM
Venue: New York Marriott Marquis
TAU2020 Global Conference
Date: Wednesday, February 12, 2020
Lightning Poster Session: Liberty Ballroom, 1:45 - 2:45 PM
Poster Session: “A small molecule inhibitor of tau self-association is efficacious in both htau and JNPL3 mouse models of tauopathy.” 7:30 AM - 6:40 PM
Venue: Marriott Marquis Washington, D.C.
About Oligomerix’s Lead Program
Oligomerix’s lead candidate is a small molecule inhibitor of tau self-association and targets the beginning of the tau aggregation cascade. The activity of the drug translated from in vitro and cell assays to animal studies, validating the company’s screening approach. In vivo proof-of-concept studies demonstrated compound efficacy in two transgenic mouse models with tau pathology representative of AD and frontotemporal dementia. In a study recently published in the Journal of Alzheimer’s Disease, Oligomerix and the Feinstein Institutes for Medical Research reported that the compound inhibited hippocampal self-associated tau in the htau mouse model of tauopathy which expresses the six CNS isoforms of the human tau protein. Initial preclinical safety studies show the drug is well tolerated with no adverse events or behavioral abnormalities observed. The compound is being developed with an accompanying novel biomarker.
About Oligomerix, Inc.
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.
Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit http://www.oligomerix.com.